Pulmonary haemorrhage and haemoptysis associated with bevacizumab-related treatment regimens: a retrospective, pharmacovigilance study using the FAERS database
暂无分享,去创建一个
Huiping Hu | R. You | Jinmei Liu | Cong Zhang | Zhiwen Fu | Shijun Li | Yu Zhang
[1] P. Catalano,et al. Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200 , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] R. Herbst,et al. Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Dehua Wu,et al. Interstitial pneumonitis associated with combined regimen of immunotherapy and conventional therapies—pharmacovigilance database analysis with real-world data validation , 2023, BMC Medicine.
[4] Q. Cheng,et al. Adverse reactions associated with immune checkpoint inhibitors and bevacizumab: A pharmacovigilance analysis , 2022, International journal of cancer.
[5] Y. Kanbayashi,et al. Evaluation of lung toxicity with bevacizumab using the spontaneous reporting database , 2022, Scientific Reports.
[6] Junyan Wu,et al. Stevens-Johnson syndrome/toxic epidermal necrolysis in patients treated with immune checkpoint inhibitors: A safety analysis of clinical trials and FDA pharmacovigilance database , 2021, EClinicalMedicine.
[7] J. Pacheco,et al. Immune-related adverse event profile of combination treatment of PD-(L)1 checkpoint inhibitors and bevacizumab in non-small cell lung cancer patients: data from the FDA adverse event reporting system , 2021, Translational lung cancer research.
[8] Shusen Sun,et al. Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system , 2020, BMC pharmacology & toxicology.
[9] O. Chinot,et al. Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook. , 2020, Cancer treatment reviews.
[10] T. Taguchi,et al. Predictive factors for the development of proteinuria in cancer patients treated with bevacizumab, ramucirumab, and aflibercept: a single-institution retrospective analysis , 2020, Scientific Reports.
[11] Jin-fang Xu,et al. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system , 2019, Journal of Immunotherapy for Cancer.
[12] R. Nishikawa,et al. Safety and effectiveness of bevacizumab in Japanese patients with malignant glioma: a post-marketing surveillance study , 2019, Japanese journal of clinical oncology.
[13] Marc P. Bonaca,et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. , 2018, The Lancet. Oncology.
[14] Tetsuya Tanimoto,et al. EGFR–TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients With Non–Small Cell Lung Cancer , 2018, JAMA oncology.
[15] M. Kusumoto,et al. Bevacizumab for non‐small‐cell lung cancer: A nested case control study of risk factors for hemoptysis , 2016, Cancer science.
[16] H. Uetake,et al. Bevacizumab safety in Japanese patients with colorectal cancer. , 2016, Japanese journal of clinical oncology.
[17] Kunihiko Takahashi,et al. Effect of database profile variation on drug safety assessment: an analysis of spontaneous adverse event reports of Japanese cases , 2015, Drug design, development and therapy.
[18] D. Shin,et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. , 2013, The Lancet. Oncology.
[19] L. Leibovici,et al. The Impact of Bevacizumab (Avastin) on Survival in Metastatic Solid Tumors - A Meta-Analysis and Systematic Review , 2013, PloS one.
[20] N. Petrelli,et al. Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] P. Garrido,et al. MO19390 (SAiL): bleeding events in a phase IV study of first-line bevacizumab with chemotherapy in patients with advanced non-squamous NSCLC. , 2012, Lung cancer.
[22] F. Zhu,et al. A Phase II Study of Capecitabine, Oxaliplatin, and Cetuximab with or Without Bevacizumab as Frontline Therapy for Metastatic Colorectal Cancer. A Fox Chase Extramural Research Study , 2012, Journal of Gastrointestinal Cancer.
[23] C. Henschke,et al. Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[24] Shenhong Wu,et al. Increased Risk of Serious Hemorrhage with Bevacizumab in Cancer Patients: A Meta-Analysis , 2010, Oncology.
[25] A. Bate,et al. Quantitative signal detection using spontaneous ADR reporting , 2009, Pharmacoepidemiology and drug safety.
[26] R. Ramlau,et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] H. Verheul,et al. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition , 2007, Nature Reviews Cancer.
[28] D. McDonald,et al. Mechanisms of adverse effects of anti-VEGF therapy for cancer , 2007, British Journal of Cancer.
[29] J. Verweij,et al. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. , 2006, European journal of cancer.
[30] Kenneth J. Hillan,et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer , 2004, Nature Reviews Drug Discovery.
[31] M. Wolzt,et al. Large amounts of vascular endothelial growth factor at the site of hemostatic plug formation in vivo. , 1999, Arteriosclerosis, thrombosis, and vascular biology.
[32] D. Berry,et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] R. Greil,et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. , 2013, The Lancet. Oncology.
[34] T. Yoshino,et al. [Bevacizumab (Avastin)]. , 2007, Gan to kagaku ryoho. Cancer & chemotherapy.